Acurx Pharmaceuticals (FRA:3ZO0) Inventories, Work In Process: €0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:3ZO0 Acurx Pharmaceuticals Inc FRA:3ZO0
35 GF Score
Price €5.09
! 1 Warning Sign
View Full Analysis

What is Acurx Pharmaceuticals Inventories, Work In Process?

Acurx Pharmaceuticals FRA:3ZO0 35 Inventories, Work In Process is €0.00 Mil as of Mar. 2026. GuruFocus rates FRA:3ZO0 with a GF Score™ of 35/100. The stock has 1 warning sign investors should review.

Work in process is the part of a manufacturer's inventory that is in the production process and has not yet been completed and transferred to the finished goods inventory. Acurx Pharmaceuticals's work in process for the quarter that ended in Mar. 2026 was €0.00 Mil.

Acurx Pharmaceuticals Inventories, Work In Process Historical Data

* Premium members only.

The historical data trend for Acurx Pharmaceuticals's Inventories, Work In Process can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Acurx Pharmaceuticals Inventories, Work In Process Chart

Acurx Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Work In Process
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Acurx Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventories, Work In Process Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:3ZO0
35GF Score
Acurx Pharmaceuticals Inc FRA:3ZO0
Inventories, Work In Process is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Acurx Pharmaceuticals Inventories, Work In Process Calculation

That part of a manufacturer's inventory that is in the production process and has not yet been completed and transferred to the finished goods inventory. This account contains the cost of the direct material, direct labor, and factory overhead placed into the products on the factory floor. A manufacturer must disclose in its financial statements the cost of its work-in-process as well as the cost of finished goods and materials on hand.

What does a Inventories, Work In Process of €0.00 Mil mean?
Acurx Pharmaceuticals (FRA:3ZO0) has a Inventories, Work In Process of €0.00 Mil as of Mar. 2026. Work in progress is the portion of inventory containing goods that are unfinished. View historical data on Acurx Pharmaceuticals and its competitors.
Is Acurx Pharmaceuticals' Inventories, Work In Process too high?
Acurx Pharmaceuticals' current Inventories, Work In Process is €0.00 Mil. Overall, Acurx Pharmaceuticals has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Acurx Pharmaceuticals' Inventories, Work In Process compare to KAPA and PULM?
Acurx Pharmaceuticals' Inventories, Work In Process of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Work In Process for a Biotechnology company?
A good Inventories, Work In Process depends on the Biotechnology industry context. However, Inventories, Work In Process should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Work In Process mean?
A high Inventories, Work In Process can signal that a stock is expensive relative to its fundamentals. Work in progress is the portion of inventory containing goods that are unfinished. View historical data on Acurx Pharmaceuticals and its competitors. Acurx Pharmaceuticals's current Inventories, Work In Process is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acurx Pharmaceuticals stock overvalued right now?
Acurx Pharmaceuticals (FRA:3ZO0) has a current Inventories, Work In Process of €0.00 Mil. The current Inventories, Work In Process is €0.00 Mil. Acurx Pharmaceuticals' overall GF Score™ is 35/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Work In Process calculated?
Inventories, Work In Process is calculated from a company's financial statements. For Acurx Pharmaceuticals (FRA:3ZO0), the current Inventories, Work In Process is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Acurx Pharmaceuticals Business Description

Other Exchanges ACXP:USA
Address 259 Liberty Avenue, Staten Island, NY, USA, 10305
Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.
35GF Score

Get the complete analysis for FRA:3ZO0

Inventories, Work In Process is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.09
Price